The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Bruker P/E ratio is 34.43. it has decreased in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Bruker’s P/E ratio
What is Bruker P/E Ratio?
The Bruker P / E ratio is 34.43, which represents a 30.99% decrease from the same period last year. their average P/E ratio is 39.89 and their 5-year average is 22.2.
What is Bruker Net EPS?
Bruker’s net profit from the most recent quarter was 1.87 US dollars, which represents a 20.65% increase over the same period last year.
Who are Bruker Competitors?
Based on Jika.io AI model, China Isotope & Radiation, AptarGroup, Bio-Rad Laboratories, Cardinal Health, CONMED, Integer Holdings, QuidelOrtho, Tecan Group AG are considered to be Bruker’s competitors because the companies operate within the same industry as Bruker and they are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Bruker.
Who is Bruker’s Biggest competitor?
Bruker’s biggest competitor is China Isotope & Radiation based on the Jika.io AI model. it has a similar market capitalization to Bruker in the industry, it dominates a similar share of the market as Bruker, and it provides and markets very similar services.
What industry is Bruker in?
Bruker is part of the Medical Devices industry and the Healthcare sector.
Bruker vs China Isotope & Radiation
Market Cap: Bruker’s Market Cap of 9634411520 is higher than China Isotope & Radiation Market Cap of 6077625344.
Average Volume: Bruker’s Average Volume of 777395.0 is higher than China Isotope & Radiation Average Volume of 56416.0.
Beta: Bruker’s Beta of 1.25 is higher than China Isotope & Radiation Beta of 0.82.
Revenue: Bruker’s Revenue of 2.418B is lower than China Isotope & Radiation Revenue of 5.144B.
Net Income: Bruker’s Net Income of 277.1M is lower than China Isotope & Radiation Net Income of 335.751M.
Gross Profit: Bruker’s Gross Profit of 1.21B is lower than China Isotope & Radiation Gross Profit of 3.242B.
Ebitda: Bruker’s Ebitda of 479.2M is lower than China Isotope & Radiation Ebitda of 501.195M.
P/E Ratio: Bruker’s P/E Ratio of 34.89 is higher than China Isotope & Radiation P/E Ratio of 15.45.
P/S Ratio: Bruker’s P/S Ratio of 3.95 is higher than China Isotope & Radiation P/S Ratio of 1.6.
P/B Ratio: Bruker’s P/B Ratio of 9.55 is higher than China Isotope & Radiation P/B Ratio of 1.45.
P/FCF Ratio: Bruker’s P/FCF Ratio of 55.19 is higher than China Isotope & Radiation P/FCF Ratio of -174.14.
ROE: Bruker’s ROE of 0.27 is higher than China Isotope & Radiation ROE of 0.08.
ROA: Bruker’s ROA of 0.08 is higher than China Isotope & Radiation ROA of 0.03.
Return On Capital Employed: Bruker’s Return On Capital Employed of 0.16 is higher than China Isotope & Radiation Return On Capital Employed of 0.1.
Gross Profit Margin: Bruker’s Gross Profit Margin of 0.5 is lower than China Isotope & Radiation Gross Profit Margin of 0.71.
Assets (Total): Bruker’s Assets (Total) of 3.65B is higher than China Isotope & Radiation Assets (Total) of 10.474B.
Bruker vs AptarGroup
Market Cap: Bruker’s Market Cap of 9634411520 is higher than AptarGroup Market Cap of 6730422784.
Average Volume: Bruker’s Average Volume of 777395.0 is higher than AptarGroup Average Volume of 285108.0.
Beta: Bruker’s Beta of 1.25 is higher than AptarGroup Beta of 0.62.
Revenue: Bruker’s Revenue of 2.418B is lower than AptarGroup Revenue of 3.227B.
Net Income: Bruker’s Net Income of 277.1M is higher than AptarGroup Net Income of 244.097M.
Gross Profit: Bruker’s Gross Profit of 1.21B is higher than AptarGroup Gross Profit of 1.157B.
Ebitda: Bruker’s Ebitda of 479.2M is lower than AptarGroup Ebitda of 587.251M.
P/E Ratio: Bruker’s P/E Ratio of 34.89 is higher than AptarGroup P/E Ratio of 31.1.
P/S Ratio: Bruker’s P/S Ratio of 3.95 is higher than AptarGroup P/S Ratio of 2.05.
P/B Ratio: Bruker’s P/B Ratio of 9.55 is higher than AptarGroup P/B Ratio of 3.4.
P/FCF Ratio: Bruker’s P/FCF Ratio of 55.19 is higher than AptarGroup P/FCF Ratio of 101.82.
ROE: Bruker’s ROE of 0.27 is higher than AptarGroup ROE of 0.11.
ROA: Bruker’s ROA of 0.08 is higher than AptarGroup ROA of 0.05.
Return On Capital Employed: Bruker’s Return On Capital Employed of 0.16 is higher than AptarGroup Return On Capital Employed of 0.1.
Gross Profit Margin: Bruker’s Gross Profit Margin of 0.5 is higher than AptarGroup Gross Profit Margin of 0.36.
Assets (Total): Bruker’s Assets (Total) of 3.65B is lower than AptarGroup Assets (Total) of 4.141B.
Debt (Total): Bruker’s Debt (Total) of 1.334B is higher than AptarGroup Debt (Total) of 1.245B.
Shareholders Equity: Bruker’s Shareholders Equity of 1.085B is lower than AptarGroup Shareholders Equity of 1.969B.
Bruker vs Bio-Rad Laboratories
Market Cap: Bruker’s Market Cap of 9634411520 is lower than Bio-Rad Laboratories Market Cap of 15088627712.
Average Volume: Bruker’s Average Volume of 777395.0 is higher than Bio-Rad Laboratories Average Volume of 211511.0.
Beta: Bruker’s Beta of 1.25 is higher than Bio-Rad Laboratories Beta of 0.92.
Revenue: Bruker’s Revenue of 2.418B is lower than Bio-Rad Laboratories Revenue of 2.923B.
Net Income: Bruker’s Net Income of 277.1M is lower than Bio-Rad Laboratories Net Income of 4.246B.
Gross Profit: Bruker’s Gross Profit of 1.21B is lower than Bio-Rad Laboratories Gross Profit of 1.641B.
Ebitda: Bruker’s Ebitda of 479.2M is lower than Bio-Rad Laboratories Ebitda of 5.574B.
P/E Ratio: Bruker’s P/E Ratio of 34.89 is higher than Bio-Rad Laboratories P/E Ratio of -150.81.
P/S Ratio: Bruker’s P/S Ratio of 3.95 is lower than Bio-Rad Laboratories P/S Ratio of 5.27.
P/B Ratio: Bruker’s P/B Ratio of 9.55 is higher than Bio-Rad Laboratories P/B Ratio of 1.5.
P/FCF Ratio: Bruker’s P/FCF Ratio of 55.19 is higher than Bio-Rad Laboratories P/FCF Ratio of 31.25.
ROE: Bruker’s ROE of 0.27 is higher than Bio-Rad Laboratories ROE of -0.01.
ROA: Bruker’s ROA of 0.08 is higher than Bio-Rad Laboratories ROA of -0.01.
Return On Capital Employed: Bruker’s Return On Capital Employed of 0.16 is higher than Bio-Rad Laboratories Return On Capital Employed of 0.04.
Gross Profit Margin: Bruker’s Gross Profit Margin of 0.5 is lower than Bio-Rad Laboratories Gross Profit Margin of 0.57.
Assets (Total): Bruker’s Assets (Total) of 3.65B is higher than Bio-Rad Laboratories Assets (Total) of 17.776B.
Debt (Total): Bruker’s Debt (Total) of 1.334B is lower than Bio-Rad Laboratories Debt (Total) of 223.376M.
Shareholders Equity: Bruker’s Shareholders Equity of 1.085B is lower than Bio-Rad Laboratories Shareholders Equity of 13.667B.
Bruker vs Cardinal Health
Market Cap: Bruker’s Market Cap of 9634411520 is lower than Cardinal Health Market Cap of 14340557824.
Average Volume: Bruker’s Average Volume of 777395.0 is higher than Cardinal Health Average Volume of 2.588M.
Beta: Bruker’s Beta of 1.25 is higher than Cardinal Health Beta of 0.83.
Revenue: Bruker’s Revenue of 2.418B is higher than Cardinal Health Revenue of 162.467B.
Net Income: Bruker’s Net Income of 277.1M is lower than Cardinal Health Net Income of 611.0M.
Gross Profit: Bruker’s Gross Profit of 1.21B is lower than Cardinal Health Gross Profit of 6.778B.
Ebitda: Bruker’s Ebitda of 479.2M is higher than Cardinal Health Ebitda of 1.285B.
P/E Ratio: Bruker’s P/E Ratio of 34.89 is higher than Cardinal Health P/E Ratio of -15.38.
P/S Ratio: Bruker’s P/S Ratio of 3.95 is higher than Cardinal Health P/S Ratio of 0.08.
P/B Ratio: Bruker’s P/B Ratio of 9.55 is higher than Cardinal Health P/B Ratio of -21.07.
P/FCF Ratio: Bruker’s P/FCF Ratio of 55.19 is higher than Cardinal Health P/FCF Ratio of 32.93.
ROE: Bruker’s ROE of 0.27 is higher than Cardinal Health ROE of -1.09.
ROA: Bruker’s ROA of 0.08 is higher than Cardinal Health ROA of -0.02.
Return On Capital Employed: Bruker’s Return On Capital Employed of 0.16 is higher than Cardinal Health Return On Capital Employed of -0.04.
Gross Profit Margin: Bruker’s Gross Profit Margin of 0.5 is higher than Cardinal Health Gross Profit Margin of 0.04.
Assets (Total): Bruker’s Assets (Total) of 3.65B is lower than Cardinal Health Assets (Total) of 44.453B.
Debt (Total): Bruker’s Debt (Total) of 1.334B is lower than Cardinal Health Debt (Total) of 6.236B.
Shareholders Equity: Bruker’s Shareholders Equity of 1.085B is lower than Cardinal Health Shareholders Equity of 1.791B.
About Bruker
Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States and internationally. the company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO and Bruker Energy & Supercon Technologies. it offers life science tools and single and multiple modes of measurement; life science mass spectrometry; MALDI Biotyper Rapid Pathogen Identification Platform and related test kits, DNA test strips and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. it also provides a range of portable analytical and bioanalytical detection systems and related products; X-ray instruments; analytical tools for electron microscopes; handheld, portable and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instruments; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect detection and photomask repair and cleaning equipment. in addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support multi-omics needs of researchers in translational research, drug discovery and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology instruments, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. the company was established in 1991 and is based in Billerica, Massachusetts.
